NDATOPICALGEL
Approved
Apr 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
TEMOVATE (clobetasol propionate) by Sandoz is clinical pharmacology: the corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. First approved in 1994.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Temovate is a ultra-potent topical corticosteroid (clobetasol propionate 0.05%) formulated as a gel for dermatologic use. It treats inflammatory skin conditions including psoriasis and seborrheic dermatitis by suppressing local immune and inflammatory responses. The drug works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms characteristic of corticosteroid class agents.
LOE Approaching
As a mature, off-patent topical with declining exclusivity, brand roles are focused on defending market share against generics and biosimilar competitors; team size typically contracts during LOE phase.
Mechanism of Action
CLINICAL PHARMACOLOGY: The corticosteroids are a class of compounds comprising steroid hormones secreted by the adrenal cortex and their synthetic analogs. In pharmacologic doses, corticosteroids are used primarily for their anti-inflammatory and/or immunosuppressive effects. Topical…
Worked on TEMOVATE at Sandoz? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.